Tuesday 13 October 2026 Export ARVN’s income statement to Excel — free account

Arvinas, Inc.

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.27 0.18 −2.42%

Follow ARVN

Alert me

Market cap: $487.1M
P/E: 57.3×
Fwd P/E: −2.7×
Dividend yield: —
F-score: 5/9
Altman Z: −0.61
Beneish M: −1.60
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.27

Total sells 1.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	1	—	—	9	1	—	6	2	—	—	—	—

Insider Ownership 9.57%

Capital & Financial Ratios $m

Market Cap 487.13

Revenue 316.70

Net Income 9.30

Free Cash Flow (208.80)

Net Debt (567.60)

Current Ratio 7.91

Debt/Equity 0.00

P/E ratio 57.31

Fwd P/E (2.68)

P/S ratio 1.52

P/B ratio 0.86

Past 5Y EPS Growth —

This Y EPS Growth 96.43%

Next Y EPS Growth (8,053.92%)

Next Y revenue growth 12.76%

Next 5Y EPS Growth (23.43%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 5.15%

10-year low 10-year high

P/B against its own 10 years 3.37%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,267	1,039	685	568
Receivables	7	14	6	54
Inventory	—	—	—	—
Other	—	—	—	—
	1,280	1,067	701	652

	2023	2024	2025	Q'26
Payables	92	72	70	52
ST’ Debt	—	—	—	—
Other	—	—	—	28
	257	230	143	83

Compound Annual Growth %

	10y	5y	3y
Sales	—	58.93%	25.96%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(7.54%)	(8.42%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	16	250	—	—	—
’25	189	22	42	10	263
’24	25	77	102	59	263
’23	33	55	35	(43)	79
’22	27	34	33	38	131
’21	6	6	9	33	54
’20	6	6	8	6	26

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(69)	(48)	—	—	—
’25	(89)	(95)	(59)	(30)	(274)
’24	(97)	50	(128)	(84)	(259)
’23	(91)	(89)	(85)	(83)	(348)
’22	(57)	(79)	(67)	(71)	(273)
’21	(39)	(47)	682	(36)	559
’20	(17)	(21)	(22)	(29)	(90)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(70)	(48)	—	—	—
’25	(89)	(97)	(59)	(31)	(276)
’24	(98)	50	(129)	(84)	(261)
’23	(92)	(89)	(86)	(83)	(351)
’22	(59)	(80)	(69)	(72)	(280)
’21	(40)	(48)	680	(38)	555
’20	(18)	(23)	(24)	(31)	(96)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.90)	2.58	—	—	—
’25	1.14	(0.84)	(0.48)	(1.10)	(1.14)
’24	(0.97)	(0.49)	(0.68)	(0.63)	(2.77)
’23	(1.54)	(1.25)	(1.18)	(2.53)	(6.62)
’22	(1.20)	(1.32)	(1.24)	(1.56)	(5.31)
’21	(0.84)	(1.03)	(0.94)	(1.00)	(3.82)
’20	(0.56)	(0.65)	(0.79)	(0.99)	(3.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	10.19	12.29	19.68	56.59	31.54	13.57	17.37	5.90	Analyst estimates 2026–2028 Powerpack
	High	—	—	21.25	44.97	86.44	108.47	82.86	42.84	53.08	21.00
People
People	Employees	—	72	83	133	179	280	415	445	430	246
	Revenue/emp, $m	0.00	0.11	0.17	0.32	0.14	0.19	0.32	0.18	0.61	1.07
Income, $m
Income, $m	Revenue	7	8	14	43	26	54	131	79	263	263
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(14)	(24)	(41)	(46)	(115)	(184)	(251)	(364)	(198)	(80)
	EBT margin, %	(216.50)	(317.32)	(289.59)	(106.05)	(444.79)	(343.47)	(191.02)	(463.57)	(75.28)	(30.65)
	Net income	(14)	(24)	(41)	(70)	(119)	(191)	(282)	(367)	(199)	(81)
	Depreciation	1	1	1	3	6	16	16	(9)	(11)	(3)
Per share, $
Per share, $	Revenue	3.51	4.00	1.52	1.31	0.66	1.07	2.47	1.41	3.66	3.70
	Earnings	(7.56)	(12.68)	(25.45)	(2.13)	(3.02)	(3.82)	(5.31)	(6.62)	(2.77)	(1.14)
	Cash flow	(10.22)	2.70	(1.71)	(1.23)	(2.27)	11.19	(5.14)	(6.27)	(3.61)	(3.86)
	Capex	(0.14)	(0.53)	(0.30)	(0.19)	(0.16)	(0.09)	(0.13)	(0.05)	(0.02)	(0.03)
	Free cash flow	(10.36)	2.16	(2.01)	(1.43)	(2.43)	11.09	(5.27)	(6.32)	(3.63)	(3.89)
	Book value	12.66	0.13	14.50	6.89	16.26	15.63	10.62	11.89	7.81	6.12
	Shares, m	2	2	9	33	40	50	53	56	72	71
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	8.45	31.44	129.53	76.62	13.51	32.30	5.23	3.20
	P/B	0.00	0.00	0.89	5.96	5.22	5.25	3.14	3.84	2.45	1.94
	EV/Sales	0.00	0.00	(4.51)	24.97	103.06	48.54	4.31	16.20	1.29	0.60
	EV/FCF	(0.46)	(0.46)	3.41	(22.89)	(27.77)	4.69	(2.02)	(3.63)	(1.31)	(0.57)
Cash, $m
Cash, $m	Operating cash flow	(19)	5	(16)	(41)	(90)	559	(273)	(348)	(259)	(274)
	Capex	0	(1)	(3)	(6)	(6)	(5)	(7)	(3)	(2)	(2)
	Free cash flow	(20)	4	(19)	(47)	(96)	555	(280)	(351)	(261)	(276)
Balance, $m
Balance, $m	Working capital	27	48	173	258	654	1,291	945	1,023	838	558
	Total debt	0	0	2	2	2	1	1	1	1	0
	Net debt	(35)	(39)	(186)	(279)	(687)	(1,506)	(1,210)	(1,266)	(1,039)	(685)
	Shareholders’ equity	24	0	137	227	642	782	565	660	562	434
Returns, %
Returns, %	ROA	(23.54)	(54.63)	(180.25)	(28.07)	(23.41)	(16.62)	(19.82)	(28.55)	(16.60)	(8.93)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	26.32	60.82	(635.93)	(38.70)	(27.46)	(26.83)	(41.96)	(59.97)	(32.56)	(16.23)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OCS Oculis Holding AG	$514.9M	— (loss-making)	— (loss-making)	+23.96% (above 0%: growing)	n/m	−10.40% (below 0%: shrinking)	100.00%	(7,603.42%)	Compare
ALT Altimmune, Inc.	$507.7M	— (loss-making)	— (loss-making)	+520.00% (above 0%: growing)	n/m	−25.27% (below 0%: shrinking)	100.00%	0.00%	Compare
ALLO Allogene Therapeutics, Inc.	$504.4M	— (loss-making)	— (loss-making)	+20,990.91% (above 0%: growing)	n/m	+17.73% (above 0%: growing)	100.00%	(1,011.21%)	Compare
CTNM Contineum Therapeutics, Inc.	$503.4M	— (loss-making)	—	—	n/m	+26.73% (above 0%: growing)	100.00%	0.00%	Compare
ARVN Arvinas, Inc.	$499.6M	57.3×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%
EPRX Eupraxia Pharmaceuticals Inc.	$491.7M	— (loss-making)	—	—	n/m	−56.41% (below 0%: shrinking)	—	0.00%	Compare
MPLT MapLight Therapeutics, Inc.	$490.7M	— (loss-making)	—	—	n/m	−31.91% (below 0%: shrinking)	—	0.00%	Compare
AUTL Autolus Therapeutics PLC Sponsored ADR	$481.8M	— (loss-making)	— (loss-making)	+118.37% (above 0%: growing)	n/m	+67.55% (above 0%: growing)	55.20%	(95.95%)	Compare
OVID Ovid Therapeutics	$480.4M	— (loss-making)	— (loss-making)	+463.85% (above 0%: growing)	n/m	−268.54% (below 0%: shrinking)	100.00%	(2,141.61%)	Compare
Median of peers	$497.5M	—	—	+463.85%	—	−17.83%	100.00%	(47.97%)

All 614 Biotechnology stocks →

Arvinas, Inc. (ARVN) key facts

Arvinas, Inc. (ARVN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.
As of October 12, 2026, ARVN traded at $7.45, a market capitalization of $487.1 million.
Return on equity was −16.2% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.61 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.